Research Project 2 (RP2) is based on preliminary data and studies performed during ICMIC 2. The goal of this project is to develop non-invasive methods to distinguish indolent from aggressive cancers and to monitor evolution of a tumor to a more malignant state. These very pragmatic issues of cancer care are relevant to many patients and are of high potential impact. The central theme of this project is the integration of non-invasive imaging in the development of new paradigms to advance cancer care.
In Aim 1 we propose to determine whether elevated lactate is a general characteristic of tumors with genetic mutations activating the PTEN/PI3K/AKT, Our goal is broader and is to determine whether this is a general characteristic of a more aggressive/metastatic tumor phenotype. Since PTEN/PI3K/AKT mutations and deletions are commonly present in aggressive/metastatic tumors and a poor prognostic factor across multiple tumor types, we focus on this signaling pathway. A series of isogenic tumors across a broad range of cancers (breast, prostate, colon, glioma) will be studied. We will determine if lactate levels, LDHA expression, glucose and glutamine metabolism, and gene array profiles are concordant. We will determine if the MRS-determined metabolic changes/differences are concordant with measures of ^^FDG uptake, gene array profile analyses (in collaboration with RP4), and phenotypic behavior (growth, metastases) in prostate and other tumor models.
In Aim 2 we will determine if LDH-A is potentially an important target for developing new anti-neoplastic drugs and whether MRS measurements can be used as a non-invasive measure of target inhibition.
In Aim 3 we will collaborate with RP 3 and 4 to determine if changes in metabolism can be used as an early marker of response to novel specific targeted therapies. We will perform MRS and PET (RP4) studies on novel therapies that are, or will shortly be in clinical evaluation. We hypothesize that successful therapy will induce a lower glycolytic (and glutaminolytic) state and will be reflected in tumor metabolism (lactate levels, glycolytic and glutaminolytic rates and ^^FDG uptake). Our long term goal is to translate the preclinical MR imaging results obtained in.this project to comparable clinical imaging studies.

Public Health Relevance

RP2 is a preclinical study, but is designed to be readily translated to the clinic. We address a critical question of determining which patients need to be treated and when do they need treatment. These preclinical studies will demonstrate that non-invasive metabolic measurements can: 1) predict aggressive tumor behavior, 2) can be used as a marker for developing and optimizing new drugs, and/or 3) predict treatment response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086438-13
Application #
8567118
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$231,331
Indirect Cost
$104,695
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Cheal, Sarah M; Xu, Hong; Guo, Hong-fen et al. (2014) Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther 13:1803-12
de Biasi, Andreas R; Villena-Vargas, Jonathan; Adusumilli, Prasad S (2014) Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 20:5384-91
Vargas, Hebert Alberto; Wassberg, Cecilia; Fox, Josef J et al. (2014) Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 271:220-9
Adusumilli, Prasad S (2014) Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma. Cancer 120:3268-71
Eguchi, Takashi; Kadota, Kyuichi; Park, Bernard J et al. (2014) The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210-22
Zhang, Hanwen; Huang, Ruimin; Pillarsetty, NagaVaraKishore et al. (2014) Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging 41:322-32
Cheal, Sarah M; Punzalan, Blesida; Doran, Michael G et al. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino Eur J Nucl Med Mol Imaging 41:985-94
Zhang, Hanwen; Huang, Ruimin; Cheung, Nai-Kong V et al. (2014) Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res 20:2182-91
Beattie, Bradley J; Pentlow, Keith S; O'Donoghue, Joseph et al. (2014) A recommendation for revised dose calibrator measurement procedures for 89Zr and 124I. PLoS One 9:e106868
Lee, Ming-Ching; Buitrago, Daniel H; Kadota, Kyuichi et al. (2014) Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas. Lung Cancer Manag 3:245-253

Showing the most recent 10 out of 119 publications